Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 113 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Mobocertinib for locally advanced or metastatic NSCLC	TAK-788 (AP32788; Mobocertinib)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2021	View \| Download
Nintedanib in combination with Pemetrexed and Cisplatin for Unresectable Malignant Pleural Mesothelioma – first line	Cisplatin (Platinol) , Nintedanib (Vargatef; Ofev; nintedanib esilate) , Pemetrexed (Alimta; pemetrexed ditromethamine dihydrate; pemetrexed ditrometamol; pemetrexed disodium)	Malignant pleural mesothelioma (MPM)	Lung and Respiratory Cancer	2018	View \| Download
Niraparib with pembrolizumab maintenance therapy for metastatic stage III or IV non-small cell lung cancer	Niraparib (Zejula; MK 4827; JNJ 64091742; GSK 3985771; niraparib tosylate monohydrate) , Pembrolizumab (Keytruda; MK-3475)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2023	View \| Download
Nivolumab (Opdivo) in combination with platinum	Nivolumab (Opdivo; BMS-936558; ONO-4538)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2017	View \| Download
Nivolumab for adjuvant treatment of stage IB-IIIA non-small cell lung cancer	Nivolumab (Opdivo; BMS-936558; ONO-4538)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2021	View \| Download
Nivolumab in combination with chemotherapy for early-stage non-small cell lung cancer – neoadjuvant	Chemotherapy , Nivolumab (Opdivo; BMS-936558; ONO-4538)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2020	View \| Download
Nivolumab in combination with ipilimumab for early stage non-small cell lung cancer -neoadjuvant	Ipilimumab (Yervoy; BMS 734016; MDX 101) , Nivolumab (Opdivo; BMS-936558; ONO-4538)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2020	View \| Download
Nivolumab in combination with ipilimumab for malignant pleural mesothelioma – first line	Ipilimumab (Yervoy; BMS 734016; MDX 101) , Nivolumab (Opdivo; BMS-936558; ONO-4538)	Malignant pleural mesothelioma (MPM)	Lung and Respiratory Cancer	2019	View \| Download
Nivolumab in combination with ipilimumab in addition to chemotherapy for treating non-small cell lung cancer – first line	Ipilimumab (Yervoy; BMS 734016; MDX 101) , Nivolumab (Opdivo; BMS-936558; ONO-4538)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2018	View \| Download
Nivolumab with chemotherapy neoadjuvant followed by nivolumab adjuvant for treating early stage non-small-cell lung cancer	Chemotherapy , Nivolumab (Opdivo; BMS-936558; ONO-4538)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2022	View \| Download